Kornimate/medical-research-clean huggingface dataset:
thoracic spinal versus epidural anesthesia for nephrectomy in obstructive/restrictive lung disease patients

Conditions: Nephrectomy; Lung Diseases; Anesthesia

Summary: patients with respiratory disease have an increased risk of developing complications perioperatively. the use of regional anesthesia decreases this risk with better postoperative outcome. the aim of this study is to compare the safety and efficacy of thoracic spinal versus thoracic epidural anesthesia for open nephrectomy in patients with obstructive/restrictive lung disease.


Eligibility criteria:
inclusion criteria: * asa class ii or iii * mild to moderate obstructive or restrictive lung disease * open nephrectomy candidate patients exclusion criteria: * any condition contra-indicating regional anesthesia * allergic to any of the drugs used during the procedure

Keywords: mid-thoracic spinal anesthesia mid-thoracic epidural anesthesia nephrectomy lung disease
optimizing dbs electrode placement and programming

Conditions: Parkinson's Disease; Essential Tremor

Summary: deep brain stimulation (dbs) has become the primary surgical therapy for the treatment of motor symptoms associated with parkinson's disease (pd), and for essential tremor (et). although an effective and relatively safe procedure with expanding indications, opportunities exist for the optimization of the current procedure. the investigators therefore propose, in a group of patients undergoing dbs surgery for the treatment of pd or et, to use a combination of high-field imaging modalities, intraoperative electrophysiology, external sensor interfaces, and computational modeling, to gather information on the utility of using these techniques to optimize dbs electrode placement and programming.


Eligibility criteria:
inclusion criteria: * a diagnosis of idiopathic parkinson's disease or essential tremor * ability to provide informed consent exclusion criteria: * claustrophobia or other conditions that prevent undergoing mr imaging * mmse score \< 23 * significant neurological diagnosis other than pd or et. * idiopathic dystonia

Keywords: deep brain stimulation (dbs) parkinson's disease essential tremor
thigh circumference reduction study

Conditions: Reduction of Localized Excess Fat

Summary: the purpose of this study is to evaluate the cutera radio frequency (rf) device for the new indication of reduction of thigh circumference.

the purpose of this study is to evaluate the cutera radio frequency device for the new indication of reduction of thigh circumference. at investigator's discretion, each subject will receive up to three treatments on one thigh and will be scheduled for two follow-up visits after the final treatment. the treated thigh will be clinically evaluated for side effects and both treated and untreated control thigh will be measured and photographed at each visit for analysis. subjects will also be weighted at each visit and asked to fill out a survey during follow-up visits.

Eligibility criteria:
inclusion criteria: * body mass index between 20 and 35 * presence of cellulite grades ii, iii or iv according to gld scale * visible bi-lateral thigh fat thigh area to be treated to measure at least 30.0mm in vertical fold, as measured with industry standard fat caliper * subject must be able to read, understand and sign the consent form * subject must adhere to the follow-up schedule and study instructions * subject must adhere to the same diet and/or exercise routine throughout the study exclusion criteria: * significant weight fluctuation (+/-10 lbs) in the past 6 months * taking weight-loss medications/supplements * participation in any other clinical study * cellulite treatment within 3 months of the treatment * surgical or non-surgical treatments to the target area in the last 12 months, e.g., liposuction * prior treatment to the target area within the last 12 months * arteriosclerosis or weakened blood vessels * heart disease * thromboembolic disease * diagnosed or documented immune system disorders * bleeding disorders. * presence of uncontrolled hypertension * taking prescription anticoagulants * history of keloid formation * malignant tumors in the target area * diabetes * any disease or condition that could impair wound healing * skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars * infection in the target area * implanted electrical device(s) * pregnant or lactating

Keywords: cellulite adipose tissue circumference reduction thigh
stimulation of the larynx to treat unexplained chronic cough

Conditions: Cough

Summary: researchers will test the effect of non-invasive vibrotactile stimulation of the larynx on symptom severity of unexplained chronic cough.


Eligibility criteria:
inclusion criteria: * adults aged 18-88 * \>8 weeks of cough * cough visual analogue scale (vas): rating of 30 or greater on a 0-100 cough severity scale * ability to provide informed consent and independently complete questionnaires * ability to read and speak english exclusion criteria: * electronic implants (e.g., pacemaker) * currently doing speech therapy for cough * contraindications to safe or effective vts device use * no regular access to wifi internet neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, parkinson, cva, vocal fold paralysis or paresis) * untreated carotid disease * bmi \> 40 (for transmission of vts through soft tissue) * current or recent (quit \< 3 months ago) smoking * known currently infectious cause for cough (e.g., tb, pertussis, covid) * history of known or suspected aspiration pneumonia * diagnosis or clinical suspicion of chronic obstructive pulmonary disease (copd) * diagnosis or clinical suspicion of interstitial lung disease (ild) * unmanaged reflux * unmanaged allergies/postnasal drip

Keywords: chronic cough
improving detection and early action for hpv-positive oropharynx cancer

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma

Summary: this study aims to determine whether a blood test for hpv dna can improve diagnosis of hpv-positive oropharynx cancer (hpv-opc).

the diagnosis of hpv-opc is often delayed. in this study, individuals with signs or symptoms potentially related to hpv-opc, such as unexplained throat pain, tonsil or tongue base asymmetry, or a neck mass, will have their blood tested for circulating hpv dna. a positive test may indicate that their symptoms are caused by hpv-opc, and their treating physician will be encouraged to complete all the necessary testing to determine whether this is the case.

Eligibility criteria:
inclusion criteria: * neck mass present for \>2 weeks with no signs/symptoms of infection * neck mass present for \>2 weeks with signs/symptoms of infection that did not resolve with antibiotic therapy * palatine or lingual tonsillar asymmetry on physical exam * palatine or lingual tonsillar asymmetry on imaging, including asymmetric fdg uptake in palatine or lingual tonsils on pet-ct scans * unexplained throat pain for \>2 weeks that did not resolve with antibiotic therapy exclusion criteria: * known diagnosis of hpv-opc
effects of physical inactivity on insulin sensitivity, appetite, energy balance, and cardiovascular responses in humans.

Conditions: Sedentary Behavior

Summary: physical inactivity is a significant predictor of major non-communicable diseases such as type 2 diabetes (7%), cardiovascular disease (6%), musculoskeletal disorders and some cancers, and has been proposed to be the 4th leading cause of death worldwide. reduced physical activity leads to an impaired function of the hormone insulin and increased adiposity. thus, the elimination of physical inactivity would remove between 6% and 10% of the major non-communicable diseases and increase life expectancy. the aim of the study is to investigate the effects of a short-term (2-day) period of reduced physical activity, with and without a proportional decrease in energy intake, on the action of insulin to regulate blood sugar fluctuations, appetite, and cardiovascular parameters (heart rate, cardiac output, stroke volume, blood flow, arterial blood pressure, peripheral vascular resistance) in response to food ingestion.


Eligibility criteria:
inclusion criteria: * non-smoking * males and females * age (18-35 years old) * body mass index (bmi) of 18-27 kg/m2 * waist circumference \<94cm for males and \<80cm for females * ability to give informed consent exclusion criteria: * smoking * any metabolic (e.g. diabetes), endocrine (e.g. hyperthyroidism) or cardiovascular (e.g. heart or blood) abnormalities including hypertension or heart failure * clinically significant abnormalities on screening including ecg abnormalities * taking routine medication that may alter cardiovascular function and blood flow (e.g. blood pressure-lowering drugs or drugs that cause hypertension) * well trained individuals with pal\>2.00; on an energy-restricted diet or seeking to lose weight * high alcohol consumption (\<3-4 units/d for men; \<2-3 units/d for women) * females who are pregnant or lactating; self-reported allergy, intolerance or strong dislike of foods or drinks to be offered for the test breakfast, pasta meal or during the intervention period * beck depression inventory score \>10 and eating attitudes test (eat-26) score \>20 as self-reported markers of symptoms and concerns characteristic of depression and eating disorders, respectively.
a study to evaluate long-term outcomes following treatment with abt-450/ritonavir/abt-267 (abt-450/r/abt-267) and abt-333 with or without ribavirin (rbv) in adults with genotype 1 chronic hepatitis c virus (hcv) infection

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Summary: the purpose of this study was to evaluate the effect of treatment with abt-450 co-formulated with ritonavir and abt-267 (abt-450/r/abt-267) and abt-333; 3-daa regimen, with or without ribavirin (rbv) in adults with chronic hepatitis c virus genotype 1 (hcv gt1) infection.

this study (topaz-i; m14-423), was a phase 3b, open-label, multicenter study conducted outside of the united states which, together with its companion study topaz-ii (m14-222; nct 02167945) conducted in the united states, was designed with the primary objective of assessing the effect of treatment response on long-term clinical outcomes in adults with chronic hcv gt1 infection with or without compensated cirrhosis, who were either treatment-naïve or interferon/ribavirin (ifn/rbv) treatment- experienced. in both studies, participants were treated with the 3-daa regimen with or without rbv. this study consisted of a screening period of up to 42 days, a treatment period of either 12 weeks for hcv gt1a-infected subjects without cirrhosis and for hcv gt1b-infected subjects without cirrhosis or with compensated cirrhosis or 24 weeks for gt1a-infected participants with compensated cirrhosis, and a 260-week post-treatment period.

Eligibility criteria:
inclusion criteria: 1. males and females at least 18 years old at screening 2. females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control 3. chronic hepatitis c, genotype 1 infection 4. males must be surgically sterile or agree to practice acceptable forms of birth control 5. screening laboratory result indicating hcv genotype 1 infection exclusion criteria: 1. use of contraindicated medications within 2 weeks of dosing 2. abnormal laboratory tests 3. current or past clinical evidence of child-pugh b or c classification or history of liver decompensation 4. confirmed presence of hepatocellular carcinoma 5. history of solid organ transplant

Keywords: hepatitis c genotype 1 compensated cirrhosis cirrhosis naive hepatitis c hepatitis c virus treatment-experienced relapser null responder non responder
ctcs in breast cancer after neoadjuvant treatment and surgery: a multicenter, prospective clinical trial

Conditions: Breast Cancer; Circulating Tumor Cell

Summary: the gilupi cellcollector® is the first in vivo ctc isolation product worldwide, which is ce approved. this is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.


Eligibility criteria:
inclusion criteria: * female, aged ≥18 and ≤70 years; * histologically confirmed invasive breast cancer (ct2-4n0-2m0 or ct1n1-3m0 before neoadjuvant treatment); * completed neoadjuvant treamtment and surgery (within 4 years after surgery); * administered neoadjuvant chemotherapy (regardless of chemotherapy regimen); * ecog 0-1 exclusion criteria: * metastatic disease (stage iv); * female patients who are pregnancy or lactation; * uncontrollable puncture site infection or systemic infection;
neuropathways intervention for brain tumor patients

Conditions: Malignant Brain Tumor; Glioma; Coping Skills

Summary: this goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. this study was developed to help patients cope after a brain tumor diagnosis. the main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.

this study will be a prospective pilot randomized controlled trial to examine the feasibility and acceptability of a novel, population-specific intervention designed to help patients with recently-diagnosed malignant brain tumors process and cope with their illness. the specific aims are to 1) refine the neuropathways intervention based on feedback from an open pilot study (n=up to 10) with exit interviews, 2) evaluate the feasibility and acceptability of neuropathways in a pilot randomized controlled trial (n=40), and 3) explore preliminary effects of the intervention on psychological, behavioral, and cognitive outcomes.

Eligibility criteria:
inclusion criteria: * age ≥18 * massachusetts general hospital cancer center patient * within 6 weeks of diagnosis with a primary malignant brain tumor * able to speak and read in english exclusion criteria: * inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia) * deemed inappropriate to approach by patient's oncologist or study pi

Keywords: glioma supportive care psychoeducation information
plasma-based colorectal cancer screening research & development

Conditions: Colo-rectal Cancer

Summary: the objective of this clinical sample collection study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e. ajcc/uicc stages 0, i, ii, iii) prior to therapeutic intervention, and from people reporting for colorectal cancer screening by colonoscopy, prior to bowel preparation.

the objective of this clinical sample collection study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e. ajcc/uicc stages 0, i, ii, iii) prior to therapeutic intervention, and from people reporting for colorectal cancer screening by colonoscopy, prior to bowel preparation. samples in the colorectal cancer biobank will be used to: 1) assess the clinical performance of novel biomarkers for colorectal cancer screening; 2) develop improved processing workflows for the epi procolon® test; 3) develop an automated epi biskit workflow.

Eligibility criteria:
inclusion criteria: group 1 * willing and able to sign an informed consent and adhere to study requirements. * subjects with colorectal cancer preferably detected by screening (any guideline recommended modality). * colonoscopy diagnosis of colorectal cancer (crc).\* * blood sampling a minimum of 7 days after colonoscopy and before resection surgery. * = strong clinical suspicion of colorectal carcinoma is also acceptable for subject enrollment; case must have a confirmed diagnosis after surgery of crc and be accompanied by a complete final pathology report. inclusion criteria: group 2 * willing and able to sign an informed consent and adhere to study requirements. * eligible for colorectal cancer screening colonoscopy. * 45 - 84 years of age at blood sampling. * able to provide blood sample within up to 2 weeks prior to bowel prep and colonoscopy. exclusion criteria: group 1 * subject with curative biopsy during colonoscopy. * current neoadjuvant treatment. * current diagnosis of any cancer other than crc, except non-melanoma skin cancer. * known infection with hiv, hbv or hcv. exclusion criteria: group 2 * previous personal history of crc, adenomatous polyps \>10mm or sessile serrated adenomas (polyps). * familial risk for colorectal cancer (1 or more 1st degree relatives with crc; known hnpcc or fap). * history of inflammatory bowel disease. * current neoadjuvant treatment. * current diagnosis of any cancer other than crc, except non-melanoma skin cancer. * infection with hiv, hbv or hcv.

Keywords: plasma cell-free dna dna methylation
effect of rice bran and cooked navy beans on cholesterol levels in healthy children

Conditions: Hyperlipidemias

Summary: a multidisciplinary team of clinicians and researchers will conduct a pilot feasibility study to evaluate whether dietary intake of dry bean powder or rice bran or a combination is a helpful dietary recommendation to reduce total cholesterol levels in children with identified, modifiable cvd risk factors, elevated total cholesterol and obesity. consumption of dry bean powder and rice bran merit additional investigation to study feasibility and acceptability in children and how they influence their lipid levels or obesity.

children will be screened prior to participation with the expectation of enrolling 40 to randomize equally to either the control arm or one of the three intervention arms. this should assure that at least 10 participants would complete each intervention. the four groups are placebo (no bean powder or rice bran included), 1/4 cup cooked navy bean powder (17.5grams powder)/day, 15 grams rice bran/day, and combination of 9 grams of bean powder/day and 8 grams rice bran/day. participants will follow this dietary intervention by being provided a study snack, such as a banana nut muffin and strawberry-pineapple smoothie. participants will consume one snack on a daily basis for a total of four weeks (28 days). the snack options were developed by a professional chef and research dietitian to fit a set of requirements for calorie and macronutrient content based on usda food guide recommendations. the placebo group will be provided the same snacks without the inclusion of rice bran or bean powder. randomization of subjects to the dietary intervention groups will be done during the study enrollment period. randomization will be based on sex of the subject to include equal numbers of both genders across all 4 groups. all participants will consume the allocated foods daily for a total of four weeks (28 days) and will not be required to alter the rest of their diets in any other way. they will also complete a 3-day food and activity log each week, starting the week prior to the study intervention (week 0) and ending the week of their final visit (week 4).

Eligibility criteria:
inclusion criteria: * children between the ages of 8-13 years old who were screened by the healthy hearts club * non-fasting total cholesterol greater than or equal to 180 mg/dl * non-fasting ldl greater than or equal to 100mg/dl * non-fasting hdl less than 60mg/dl * willing to consume study provided ingredient (cooked dry bean powder or rice bran or combination) for 28 consecutive days. exclusion criteria: * history of food allergies and/or major dietary restrictions * taking prescribed medication * ongoing medical illness

Keywords: high cholesterol.
early detection of pressure induced tissue damage by infrared spectroscopy (odp) device

Conditions: Pressure Ulcer Not Visible

Summary: the aim of this study is to demonstrate that infrared spectroscopy is able to detect pressure injuries at a very early stage

during pressure injuries formation early sub dermal bio signal appear. by applying infrared spectroscopy at a suspicions injury site on the human body and obtaining a reflected infrared light infrared allows to determine early formation of a pressure injury/

Eligibility criteria:
inclusion criteria: * patients with stage 1 pressure injury * patients with high risk of developing pressure injury exclusion criteria: * patients with stage 2 pressure injury or higher
terlipressin given as i.v. boluses versus terlipressin given as continuous intravenous infusion in patients with cirrhosis and type 1 hepatorenal syndrome

Conditions: Cirrhosis; Type 1 Hepatorenal Syndrome

Summary: it is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 hrs. in previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr or as continuous intravenous infusion at the initial dose of 2 mg/24 h. up to now the two schedules of i.v. administration of terlipressin have never been compared. nevertheless, it has been hypothesized that continuous intravenous infusion assures a more steady profile of effect on portal pressure in patients with cirrhosis. thus, the aim of the study will be to compare terlipressin given as i.v. bolus vs terlipressin given as continuous intravenous infusion in the treatment of type 1 hrs in patients with cirrhosis.


Eligibility criteria:
inclusion criteria: * patients with cirrhosis and type 1 hrs exclusion criteria: * hcc beyond the milan criteria,septic shock (systolic arterial pressure \< 90 mmhg, * significant heart or respiratory failure, * peripheral arteriophaty clinically significant, * previous heart stroke or significant alteration of the ecg

Keywords: cirrhosis type 1 hepatorenal syndrome terlipressin albumin effective circulating volume patients with